Medtronic reported solid Q2 fiscal 2025 results with revenue increasing 5% to $8.4 billion and diluted EPS rising 46% to $0.99. The growth was driven by strong performance across most businesses, particularly in Diabetes (+12%), Neuroscience (+7%), and Cardiovascular (+6%). International markets showed robust growth of 8% while U.S. revenue grew 3%.Operating profit increased 19% to $1.6 billion, with an effective tax rate of 18.0% compared to 30.6% in the prior year period. The company maintained strong liquidity with $1.4 billion in cash and cash equivalents and $6.6 billion in current investments at quarter-end. During the quarter, Medtronic repurchased 2.9 million shares at an average price of $86.26.Looking ahead, management remains focused on innovation and market expansion while monitoring macro challenges including competitive pressures, geographic developments, and supply chain constraints. The company highlighted continued momentum in key growth drivers including the MiniMed 780G insulin pump system, Inceptiv spinal cord stimulator, and the Hugo robotic surgery platform.

Medtronic reported solid Q2 fiscal 2025 results with revenue increasing 5% to $8.4 billion and diluted EPS rising 46% to $0.99. The growth was driven by strong performance across most businesses, particularly in Diabetes (+12%), Neuroscience (+7%), and Cardiovascular (+6%). International markets showed robust growth of 8% while U.S. revenue grew 3%.Operating profit increased 19% to $1.6 billion, with an effective tax rate of 18.0% compared to 30.6% in the prior year period. The company maintained strong liquidity with $1.4 billion in cash and cash equivalents and $6.6 billion in current investments at quarter-end. During the quarter, Medtronic repurchased 2.9 million shares at an average price of $86.26.Looking ahead, management remains focused on innovation and market expansion while monitoring macro challenges including competitive pressures, geographic developments, and supply chain constraints. The company highlighted continued momentum in key growth drivers including the MiniMed 780G insulin pump system, Inceptiv spinal cord stimulator, and the Hugo robotic surgery platform.